ライフサイエンスコーパス: JAK1

1 JAK1 and JAK2 truncating mutations resulted in a lack of

2 JAK1 and JAK3 are recurrently mutated in acute lymphobla

3 JAK1 and STAT3 gain-of-function mutations were found in

4 JAK1 and STAT3 were required for proliferation and survi

5 JAK1 is a critical effector of pro-inflammatory cytokine

6 JAK1 is critical for the signal transduction of many typ

7 JAK1 mediates interferon (IFN)-gamma-regulated tumor imm

8 JAK1 regulated the expression of nearly 3,000 genes in A

9 JAK1/2 inhibitors (such as ruxolitinib and JAK inhibitor

10 hat miR-373 directly targets Janus kinase 1 (JAK1) and IFN-regulating factor 9 (IRF9), important fact

11 cellular level of Janus-activated kinase 1 (JAK1) at any time point.

12 H2-like domains of the human Janus kinase 1 (JAK1) bound to a fragment of the intracellular domain of

13 H(2)O(2) responsiveness, and Janus kinase 1 (JAK1) is required for adequate basal signaling, whereas

14 terferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion

15 ing the access of Janus-associated kinase 1 (JAK1) to the type I interferon receptor.

16 ding activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides a path toward th

17 ling antagonist by targeting Janus kinase 1 (JAK1).

18 protein (RLTPR); moesin; and Janus kinase 1 (JAK1).

19 e treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that MM

20 he development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myelo

21 its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the

22 results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemoph

23 or, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.

24 Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitinib, have been devel

25 stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-depen

26 the JAK/STAT pathway, including STAT3 (38%), JAK1 (18%), and STAT5B (3%), and in negative regulators,

27 We have found 50 JAK1 truncating mutations in 36 of 635 gynecologic tumor

28 onal patterns confirm that the interleukin-6-JAK1-STAT3 pathway is deregulated.

29 bination with activating mutations in IL-7R, JAK1, or LCK, and down-regulation of CD45 expression cau

30 ing hit 1 with a pyrazolopyridone core and a JAK1 bias was selected as the starting point for our fra

31 We have used AZD1480, a JAK1/2 inhibitor, to investigate the therapeutic potenti

32 the mutants can be partially inhibited by a JAK1/2 inhibitor.

33 It displayed a JAK1/JAK2 inhibitor profile in biochemical assays, but s

34 eliorated anemia, which was unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 s

35 y program involving activation of STAT3 in a JAK1-dependent fashion.

36 In addition, administration of a JAK1/2 kinase inhibitor alleviated the Vhlh knockout phe

37 AK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.

38 Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of hig

39 Importantly, Ruxolitinib, a JAK1 inhibitor, could rescue the phenotypic changes indu

40 Of note, ruxolitinib, a JAK1/2 inhibitor approved for the treatment of MF, had n

41 Finally, ruxolitinib, a JAK1/2 inhibitor, was effective in vivo in a xenograft A

42 Indeed, cells that originally showed a JAK1-activating mutation became resistant to inhibitors

43 Furthermore, we found that a JAK1 inhibitor dose dependently reduced IFN-gamma-contro

44 ant roles in immune function, while abnormal JAK1 activity has been linked to immunological and neopl

45 ns indicated that IL15RA signaling activated JAK1, STAT1, STAT2, AKT, PRAS40, and ERK1/2 in the absen

46 s, the compound library was screened against JAK1, resulting in the identification of a triazolopyrid

47 Although JAK1/2 inhibitor therapy is effective in decreasing the

48 itch is dependent on neuronal IL-4Ralpha and JAK1 signaling.

49 Analysis of IL-6R and JAK1 expression in HCV patients by quantitative PCR show

50 and miRNA-107 target expression of IL-6R and JAK1, respectively, in vitro and also inhibit IL-6 signa

51 -function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total approximate

52 (PDO) obtained from tumors with high AXL and JAK1 were sensitive to TP-0903 and ruxolitinib (JAK inhi

53 nine nucleotide exchange factor 1 (GBF1) and JAK1, as potential antiviral drug targets.

54 The results indicate that, through Gi and JAK1 and 2 kinases activation, CXCL12 signaling cooperat

55 PNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not

56 Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro.

57 eterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 in tran

58 with dose dependent effects on both JAK2 and JAK1 suggests that it is likely that multiple pathways a

59 Cytokine signaling dependent on JAK3 and JAK1 is critically important in chronic inflammation of

60 us kinase (JAK) inhibitor targeting JAK3 and JAK1.

61 that mdig directly interacts with c-myc and JAK1 in MM cell lines, which contributes to hyperactivat

62 hibited the RET receptor (EC(50), 42 nM) and JAK1/2/3 kinases (EC(50), 780 nM).

63 of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 3.

64 with the dual aims of improving potency and JAK1 selectivity: Optimization of the lipophilic ribose

65 defenses that rely on RIG-I, MAVS, TBK1, and JAK1.

66 Tumors with high AXL, TGFbeta, and JAK1 signaling concomitantly displayed CD133-mediated ca

67 DOs, identifies continuous AXL, TGFbeta, and JAK1-STAT3 signal activation in select tumors that may b

68 scoveries that the tyrosine kinases TYK2 and JAK1 and the transcription factors STAT1, STAT2, and IRF

69 K3A, MAP3K, MEK, RSK2, RSK4, PLK4, ULK1, and JAK1.

70 Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in

71 oundwork for repurposing clinically approved JAK1/JAK2 inhibitors for type 1 diabetes.

72 -treatment with ruxolitinib, an FDA-approved JAK1/2 inhibitor, reduced circulating activin A, preserv

73 bitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of pati

74 rs of downstream signaling molecules such as JAK1 inhibitors.

75 tumors that may be targeted by combined AXL-JAK1 inhibition.

76 servations underline the cooperation between JAK1 and JAK3 mutants in T-cell transformation and repre

77 accurate picture of the interactions between JAK1 and IFNLR1 than those given in earlier reports, ill

78 on to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

79 er, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells tran

80 Both JAK1/3 inhibitors and Tac were similarly effective in re

81 s(467)) whose presence was required for both JAK1/2 binding to betac and receptor ubiquitination.

82 model correlated with the inhibition of both JAK1 and JAK3 signaling pathways.

83 ibitor-sensitive cells are dependent on both JAK1 and STAT3 for survival.

84 her, these data indicate that targeting both JAK1- and TYK2-mediated cytokine signaling is more effec

85 After heart transplantation, both JAK1/3 inhibitors reduced early mononuclear graft infilt

86 e X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated.

87 2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein inter

88 ied by H3Y41-P marks that were diminished by JAK1 inhibition.

89 gnaling cascades not canonically mediated by JAK1.

90 response, which we show is phosphorylated by JAK1.

91 RF63 suppressed by IFN-gamma was restored by JAK1 inhibitor treatment, indicating that the inhibition

92 cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in

93 These findings clarify JAK1 signalling mechanisms and demonstrate a critical fu

94 Consequently, JAK1-deficient mice exhibit impaired apoptosis and a sig

95 Among cancer cell lines containing JAK1 truncating mutations in the Cancer Cell Line Encycl

96 tiation by increasing p38MAPK and decreasing JAK1-STAT1 phosphorylation levels, while osteogenic indu

97 JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib.

98 he IL6 receptor and its downstream effectors JAK1 and STAT3 dramatically reduced tumor cell growth.

99 ed through TJP1-mediated suppression of EGFR/JAK1/STAT3 signaling, which modulated LMP7 and LMP2 leve

100 hang et al. report that TJP1 suppresses EGFR/JAK1/STAT3-mediated signaling and increases the proteaso

101 knockdown of miR-373 in hepatocytes enhanced JAK1 and IRF9 expression and reduced HCV RNA replication

102 owing JAK1 inhibition, suggesting epigenetic JAK1 action.

103 silencing of two members of the JAK family (JAK1 and JAK2) increased the susceptibility of a variety

104 drivers in non-DS leukemia (EZH2, APC, FLT3, JAK1, PARK2-PACRG, EXT1, DLEC1, and SMC3).

105 not protect these cells from death following JAK1 inhibition, suggesting epigenetic JAK1 action.

106 d a selectivity of approximately 30-fold for JAK1- over JAK2-dependent signaling.

107 consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of J

108 mall molecule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family

109 ovo protein synthesis, and contribution from JAK1.

110 reveal that a gain-of-function JAK1 genetic variant results in a mutant protein with mo

111 nes (HNF1A, IL6ST, CTNNB1, FRK, STAT3, GNAS, JAK1, and TERT) in 607 samples of 533 HCAs from 411 pati

112 prising GATA1, the miR-23a cluster and gp130-JAK1-Stat3 pathway, that synergistically facilitates apo

113 rget multiple members of the oncogenic gp130-JAK1-Stat3 pathway, and thus reinforce their inhibition

114 nts with favorable pharmacokinetics and high JAK1/3 selectivity, but only R507 synergistically intera

115 Interestingly, high JAK1-STAT3 was associated with increased levels of AXL i

116 culminated in the identification of a highly JAK1 selective compound (31) exhibiting favorable oral b

117 eing stabilized by ISG15, sterically hinders JAK1 from binding to the IFNAR2 subunit of the IFN-I rec

118 ibition in PTEN-loss contexts and identified JAK1/STAT3 activation as a potential mediator of synergi

119 Having identified JAK1 as a possible new target for arthritis at Galapagos

120 aling pathway (IL12B, IL12RB2, TYK2, IFNGR1, JAK1, and JAK2) were hypermethylated in patients with TB

121 utually exclusive mutations affecting IL2RG, JAK1, JAK3, or STAT5B in 38 of 50 T-PLL genomes (76.0%).

122 Functionally, IL2RG-JAK1-JAK3-STAT5B mutations led to signal transducer and

123 frequency mutational activation of the IL2RG-JAK1-JAK3-STAT5B axis in the pathogenesis of T-PLL.

124 eficient cells demonstrate that the impaired JAK1 function is mainly attributable to the effect of th

125 uted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but al

126 results from activating mutations either in JAK1, JAK3, or in both kinases.

127 by acquiring another activating mutation in JAK1.

128 Similarly, homologous mutations in JAK1 prevented signaling by IFN-gamma.

129 mosaic, gain-of-function mutation (S703I) in JAK1, encoding a kinase essential for signaling downstre

130 nation of the binding modes of the series in JAK1 and JAK2 by X-ray crystallography supported the des

131 aracterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK

132 Functionally, the mutation increases JAK1 activity and transactivates partnering JAKs, indepe

133 aft inhibitors delay and reduce IL-7-induced JAK1 and JAK3 phosphorylation.

134 ppressed SMAD4/TGFbeta signaling and induced JAK1-STAT3 signaling to compensate for the loss of AXL.

135 ine kinase 3 inhibitor that does not inhibit JAK1.

136 A77 1726 inhibited JAK1, JAK2, and STAT3 tyrosine phosphorylation.

137 347 dose dependently (1 nM-10 muM) inhibited JAK1- and/or TYK2-dependent signaling from the IL-12/IL-

138 In contrast to WNV, ZIKV inhibited JAK1 and TYK2 phosphorylation following type I IFN treat

139 In vivo, the effects of inhibiting JAK1/3 signaling were examined by administering the inhi

140 substituted pyrrolopyrimidine, 24, inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of le

141 his regulatory framework helped to interpret JAK1 blockade pharmacology, different clusters being aff

142 Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in

143 studies have shown that Janus kinases (JAK), JAK1, and JAK2, play an important role in IAV replicatio

144 L7 receptor (IL7R) and signals through JAK2, JAK1, and STAT5 to drive proliferation and suppress apop

145 almost completely abrogate heteromeric (JAK2-JAK1) IFN-gamma signaling, potentially by disrupting a d

146 (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF), inactivating lesions disrupting h

147 ctional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/

148 Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine sig

149 gly, CIS interacted with the tyrosine kinase JAK1, inhibiting its enzymatic activity and targeting JA

150 rial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in p

151 rmined that the interferon-activated kinases JAK1 and TYK2 suppress proliferation of trisomy 21 fibro

152 ndent activation of the Janus family kinases JAK1 and JAK2 are hallmarks of the final common pathway

153 oring somatic mutations in the Janus kinases JAK1 and JAK2.

154 tion of the IFNAR-associated protein kinases JAK1 and TYK2, leading to reduced phosphorylation of the

155 Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signalin

156 ng MESCM through transient activation of LIF-JAK1-STAT3 signaling that delays eventual nuclear transl

157 These results suggest that localized JAK1/JAK2 inhibition may be therapeutic in a range of in

158 vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the disco

159 core features of ruxolitinib (1), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibit

160 A small molecule JAK1 inhibitor cooperated with the BTK inhibitor ibrutin

161 of JAK3 and downstream signaling molecules, JAK1, STAT5, MAPK and pS6 ribosomal protein.

162 amples and pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.

163 ng RNA sequencing, we identified several new JAK1 target genes that are upregulated during involution

164 JAK2 and JAK3 isoforms, but not JAK1, mediate CXCL12-induced LFA-1 triggering to a high

165 to unsubstituted compound 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in bioche

166 be involved in leukemogenesis (ETV6, NOTCH1, JAK1, and NF1), we identified novel recurrent mutations

167 on of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of tran

168 ch leading to the constitutive activation of JAK1/STAT3 signalling, which results in sustained proinv

169 ite of leflunomide, inhibits the activity of JAK1 and JAK3.

170 other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in

171 Both domains of JAK1 are generally well ordered, with regions not seen i

172 aneously to the FERM and SH2-like domains of JAK1.

173 Downstream of JAK1-TYK2 signaling, EHV-1 blocked the phosphorylation a

174 Transient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces

175 nisms and demonstrate a critical function of JAK1 in protection against mycobacterial infection and p

176 Specific functions of JAK1 in the context of hematopoiesis, and specifically w

177 ative analysis illustrates the importance of JAK1, RELB, and EP300 mutations driving oncogenic signal

178 The importance of JAK1/3 signaling on TH2 differentiation and development

179 Inclusion of JAK1/2 inhibitor therapy in future transplant conditioni

180 Pharmacological inhibition of JAK1 also delayed disease onset.

181 We observed that inhibition of JAK1/2 signaling resulted in reduced proliferation of ef

182 enzyme assays showed selective inhibition of JAK1/3-dependent pathways with 20-fold or greater select

183 viding partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.

184 eated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth with

185 of INCB018424, a small molecule inhibitor of JAK1 and JAK2, would provide benefit similar to systemic

186 c effect of AZD1480, a specific inhibitor of JAK1/2, in suppressing neuroinflammation and neurodegene

187 aling by anti-IL-2Ralpha Ab or inhibitors of JAK1 and JAK3 significantly reduced IFN-gamma production

188 Inhibitors of JAK1/2 improve symptoms and prolong life in myelofibrosi

189 development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, rux

190 on of IFNgammaR signaling with inhibitors of JAK1/JAK2, which are mediators of IFNgammaR signaling, r

191 ese results warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.

192 JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance

193 The loss of JAK1 uncouples interleukin-6-class ligands from their do

194 bserved for homologous Leu(857) mutations of JAK1 and JAK2 and for JAK3(L875H).

195 We identified activating mutations of JAK1 and/or STAT3 genes in approximately 20% of 88 [corr

196 ntly associated with activating mutations of JAK1 or JAK2, deletion or mutation of IKZF1, and Hispani

197 leukin-6) consistent with our observation of JAK1 hyperactivation.

198 reactive oxygen species, phosphorylation of JAK1, and dephosphorylation of SHP1, leading to STAT6 ac

199 d results in constitutive phosphorylation of JAK1.

200 forms of ALK- ALCL, even in the presence of JAK1/STAT3 mutations.

201 reveal a phosphorylation-independent role of JAK1 in signal transduction.

202 Functional studies reveal sensitivity of JAK1-mutated primary SS cells to JAK inhibitor treatment

203 JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors.

204 rein, we report the discovery of a series of JAK1-selective kinase inhibitors with high potency and e

205 ized how the gene structures of the oncogene JAK1 and the tumor suppressors KDM6A and RB1 are affecte

206 terferon family, where it pairs with JAK2 or JAK1, respectively.

207 ivity, which was induced without receptor or JAK1 co-expression.

208 alterations activating the JAK-STAT pathway (JAK1, JAK2, IL7R) identified in 63 patients (50.8% of th

209 Together, this work describes a new PERK/JAK1/STAT3 signaling pathway that elicits a feed-forward

210 As pharmacological JAK1/2 inhibitors are being developed and used in clinic

211 the synergistic action of these proapoptotic JAK1 targets is obligatory for the remodeling of the mam

212 CRLF2 rearrangements, JAK1/2 point mutations, and JAK2 fusion genes have been

213 These findings identify recurrent JAK1 truncating mutations that could contribute to tumor

214 Cells from this patient exhibit reduced JAK1 and STAT phosphorylation following cytokine stimula

215 VAMP8 knockdown resulted in reduced JAK1 and STAT1 phosphorylation and impaired induction of

216 : four in known cancer genes (ACVR2A, RNF43, JAK1, and MSH3) and three in genes not previously implic

217 s a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET

218 S703I JAK1 is not only hypermorphic for cytokine signaling but

219 lates with interleukin-13 (IL-13) secretion, JAK1/2 tyrosine phosphorylation, and reduced expression

220 on of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA

221 cacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients with ankylosing spondylitis.

222 We sought to examine a selective JAK1/3 inhibitor (R256) on differentiation of TH subsets

223 A selective JAK1/3 inhibitor was used to assay the importance of thi

224 the development of highly subtype-selective JAK1 inhibitors.

225 other JAK-STAT signaling genes (IL7R, SH2B3, JAK1) in 6.3% or other kinases (FLT3, NTRK3, LYN) in 4.6

226 ession profiling indicates that the non-SMAD JAK1/STAT pathway is essential for the expression of a s

227 Using a novel mammary gland-specific JAK1 knockout model, we demonstrate here that this tyros

228 inated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell

229 type I IFN signaling pathway by suppressing JAK1 and IRF9.

230 Sustained JAK1/STAT3 signalling is maintained by DNA methyltransfe

231 t miR-373 impairs IFN signaling by targeting JAK1/IRF9 molecules.

232 We find that JAK1 transcription was predominantly restricted to a sin

233 Together, these findings indicate that JAK1-mediated signaling cascades in skin regulate the ex

234 Here, we report that JAK1 is a constitutive TGFbetaRI binding protein and is

235 Functional assays show that JAK1 deficient cancer cells are defective in IFN-gamma-i

236 and pharmacological inhibition to show that JAK1 signaling sustains the survival of ABC DLBCL cells.

237 Further analysis showed that JAK1 V658F cooperated in vivo with PML-RARA, causing a r

238 ollective results of this study suggest that JAK1 has nonredundant roles in the activation of particu

239 The JAK1/JAK2 inhibitor AZD1480 blocked the effect of cytoki

240 The JAK1/JAK2 inhibitor ruxolitinib produced significant red

241 Increased HIF-1alpha activates the JAK1/2-STAT3 axis and enhances tumor stem-like cell self

242 timulates IL-10 production by activating the JAK1- and PI3K-signaling pathways.

243 ecreased levels of IL-12, IFN-gamma, and the JAK1, STAT1, NF-kappaB, and extracellular signal-regulat

244 n HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in

245 ha (HIF-1alpha) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 - Signal Transducer and A

246 ferentiation by inhibiting the Notch and the JAK1/STAT1/STAT3 pathways, respectively.

247 llate cells, and the cooperation between the JAK1-STAT3 and SMAD pathways is critical to the roles of

248 eukin-7, an effect that was abrogated by the JAK1/2 inhibitor ruxolitinib.

249 gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.

250 In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel t

251 rs, and matched normal tissues confirmed the JAK1 mutations and showed that these mutations are somat

252 duces cancer progression by deactivating the JAK1/STAT3 pathway.

253 AML cells were sensitive to decitabine, the JAK1/2 inhibitor ruxolitinib, or the heat shock protein

254 over, the mutations alone cannot explain the JAK1/STAT3 dependency, given that wild-type JAK1 or STAT

255 edisposition to moderate selectivity for the JAK1 isoform over JAK2.

256 germline mutations, P733L and P832S, in the JAK1 protein that mediates signalling from multiple cyto

257 t results in a single aa substitution in the JAK1 tyrosine kinase that results in hyperactivation, th

258 Reconstitution experiments in the JAK1-deficient cells demonstrate that the impaired JAK1

259 Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the

260 omatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib.

261 arthritis (RA), by specific targeting of the JAK1 pathway.

262 tokine IL-6; and (iii) downregulation of the JAK1, STAT1, NF-kappaB, and ERK1/2 pathways.

263 miR-23a cluster-mediated-inactivation of the JAK1-Stat3 pathway promotes the expression and activity

264 ought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aC

265 strate that clinically relevant doses of the JAK1/2 inhibitor ruxolitinib suppresses the harmful cons

266 improvement after the administration of the JAK1/2 inhibitor ruxolitinib.

267 abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib.

268 We compared functional effects of the JAK1/2 inhibitors momelotinib and ruxolitinib, the BTK i

269 ne whether pharmacological inhibition of the JAK1/2 not only prevents the onset of HLH immunopatholog

270 There is good evidence for activation of the JAK1/JAK2 and signal transducer and activator of transcr

271 ER stress-induced activation of the JAK1/STAT3 axis leads to expression of interleukin 6 (IL

272 In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of

273 This mutation was identical to the JAK1 V658F mutation previously found in human APL and ac

274 emcitabine were randomly assigned 1:1 to the JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus

275 of inhibiting the JAK/STAT pathway using the JAK1/2 inhibitor, AZD1480.

276 stem/progenitor cells were treated with the JAK1/2 inhibitor ruxolitinib (RUX).

277 ly, treatment of LKB1-defcient mice with the JAK1/2 inhibitor ruxolitinib dramatically decreased poly

278 These effects were additive with the JAK1/2 inhibitor ruxolitinib in vivo and in vitro.

279 Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3

280 Treatment with the JAK1/2 inhibitor ruxolitinib lowered the white blood cou

281 In both models, treatment with the JAK1/2 inhibitor ruxolitinib significantly lessened the

282 d peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number

283 hemoresistant tumors, and treatment with the JAK1/JAK2 inhibitor CYT387 reduced progression of chemor

284 These JAK1 epigenetic target genes encode important regulators

285 lly, IFNG activated CTLA4 expression through JAK1/2-dependent phosphorylation of STAT1, which bound a

286 t, widespread metastases, and sensitivity to JAK1/2 inhibition.

287 JAK1/STAT3 dependency, given that wild-type JAK1 or STAT3 was sufficient to promote cell survival in

288 d provide an example wherein a cytokine uses JAK1 and JAK2 to mediate the activation of STAT5.

289 ivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties.

290 Stat3 is phosphorylated via JAK1 and acts as a critical ALK5 (activin receptor-like

291 vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray st

292 as IL-7 receptor or IL-9 receptor, in which JAK1 is appended to the specific chain, and JAK3 is appe

293 n in iMCD patients, which was abrogated with JAK1/2 inhibition.

294 ibutes of an X-ray structure in complex with JAK1.

295 receptor abolishes stable interactions with JAK1, although it was previously shown that box2 alone i

296 We show that APLNR interacts with JAK1, modulating interferon-gamma responses in tumours,

297 mechanisms of thrombocytopenia observed with JAK1/2 inhibition.

298 rmed a molecular complex that, together with JAK1 and TYK2 kinases, controlled STAT4 activation.

299 Within JAK1 the K142, P430, and K860 frame-shift mutations were

300 se (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK(-) ALCL.